DATATRAK's Technology Driven Drug Development (TD3) Supports Clinical Trial Industry Transformation
Patient-Focused Models, Improving Adherence, and Controlling Costs All Benefit From TD3
CLEVELAND, OH--(Marketwired - January 14, 2016) - DATATRAK International, Inc. (OTCQX: DTRK), the leader in developing cloud-based, unified dClinical
/EINPresswire.com/ -- "Technology Driven Drug Development, TD3, is the concept that underlies all technology in DATATRAK's product solution portfolio. All of our customers look for every technological edge they can build into their processes. Maximizing the contribution of human and technological resources and consistently improving cost effectiveness is their daily routine. We're delighted that so many organizations are using the power of our DATATRAK ONE UX
Tim Lyons, DATATRAK's Vice President of Product Development and Operations, stated that, "Our strategic investments in technology are moving the bar to help clinical operations capitalize on the viability of their drug pipelines. The DATATRAK ONE UX
Contact DATATRAK today to schedule a demo and see for yourself how you can benefit from TD3.
DATATRAK International, the leader in developing cloud-based, unified dClinical
Join DATATRAK Thought Leaders:
Tweet: #Technology driving productivity in #clinicalresearch
About DATATRAK
DATATRAK International is a worldwide technology and services company delivering Unified dClinical
Except for the historical information contained in this press release, the statements made in this release are forward-looking statements. These forward-looking statements are made based on management's expectations, assumptions, estimates and current beliefs concerning the operations, future results and prospects of the Company and are subject to uncertainties and factors which are difficult to predict and, in many instances, are beyond the control of the Company, and which could cause actual results to differ materially from those contemplated in these forward-looking statements. For a list of certain factors that may cause actual results to differ materially from those contemplated in these forward looking statements, please see the Company's report filed with the OTCQX Market on March 13, 2015 announcing its results for the full year period ended December 31, 2014. The Company undertakes no obligation to update publicly or revise any forward-looking statement whether as a result of new information, future events or otherwise.
CONTACT:
Dorothy Radke
Director Marketing
DATATRAK International, Inc.
+1-440-443-0082
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
